SXTP
60 Degrees
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SXTP
60 Degrees Pharmaceuticals, Inc.
A growth-oriented specialty pharmaceutical company developing new treatments for infectious diseases
1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036
--
60 Degrees Pharmaceuticals, Inc., a Delaware corporation, was founded on June 1, 2022. The company is a specialty pharmaceutical company with the goal of leveraging cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. The company has successfully won regulatory approval for Arakoda, a malaria preventive treatment that has been on the market since late 2019. Currently, 60P's pipeline of research and development covers vector-borne, fungal and viral diseases utilizing the company's three future products.
Company Financials
EPS
SXTP has released its 2024 Q3 earnings. EPS was reported at -0.93, versus the expected -0.87, missing expectations. The chart below visualizes how SXTP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SXTP has released its 2024 Q4 earnings report, with revenue of 261.44K, reflecting a YoY change of 512.17%, and net profit of -2.05M, showing a YoY change of -0.13%. The Sankey diagram below clearly presents SXTP’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
